Biosimilars to treat inflammatory arthritis: the challenge of proving identity.

@article{Kay2013BiosimilarsTT,
  title={Biosimilars to treat inflammatory arthritis: the challenge of proving identity.},
  author={Jonathan Kay},
  journal={Annals of the rheumatic diseases},
  year={2013},
  volume={72 10},
  pages={
          1589-93
        }
}
The introduction of targeted biological therapies has revolutionised the treatment of patients with inflammatory joint diseases. These medications are highly effective in reducing disease activity, improving physical function, and retarding or arresting the progression of structural damage. Their relative benefits and risks have been ascertained and contraindications to their use are well known. However, the high price of these drugs has limited their widespread application. The potential… CONTINUE READING
Tweets
This paper has been referenced on Twitter 11 times. VIEW TWEETS

Citations

Publications citing this paper.
SHOWING 1-10 OF 27 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 13 REFERENCES

A phase 3 randomised controlled trial to compare CTP 13 with in fl iximab in patients with active rheumatoid arthritis : 54 week results from the PLANETRA study [ Abstract ]

  • Yoo D-H, A Racewicz, J Brzezicki
  • Ann Rheum Dis
  • 2013

The role of biosimilars in the treatment of rheumatic diseases

  • T Dorner, V Strand, G Castañeda-Hernández
  • Ann Rheum Dis
  • 2013

Ef fi cacy and safety of in fl iximab in patients with ankylosing spondylitis : results of a randomized , placebo - controlled trial ( ASSERT )

  • D vanderHeijde, B Dijkmans, P Geusens
  • Arthritis Rheum
  • 2005

Similar Papers

Loading similar papers…